An Open-label, Randomized, Three-period, Crossover, Single-dose Study to Evaluate the Effect of a Low-fat Meal and a Standard Meal on the Pharmacokinetics of DBPR108 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- DBPR108 tablets
- Conditions
- Healthy Subjects
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Peak plasma concentration (Cmax) of DBPR108
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is an open-label, randomized, three-period, crossover, single-dose study to evaluate the effects of a low-fat meal and a standard meal on the pharmacokinetics of DBPR108 and the safety and tolerability of DBPR108 under different fed states in healthy adult subjects.
Detailed Description
The objective of the study is to evaluate the effect of different meal types on the pharmacokinetics of DBPR108, a potent dipeptidylpeptidase-4 inhibitor. In this open-label, randomized, three-period, crossover study, healthy subjects will receive a single dose of DBPR108 100 mg under fasted conditions and following a low-fat meal or a standard meal. Twenty-one healthy subjects will be randomized 1:1:1 to Sequence A, Sequence B, or Sequence C. This study will consist of a screening and baseline period, a treatment period, and a follow-up period. Blood samples for pharmacokinetic assessments will be taken pre-dose and up to 48 h post-dose.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects fully understand and voluntarily participate in this study and sign informed consent;
- •Healthy male and/or female subjects between the ages of 18 and 45 years (inclusive);
- •Body Mass Index (BMI) of 18 to 28 kg/m2 (inclusive), body weight for male ≥50.0 kg and for female≥45.0 kg；
- •Subjects (including their partners) are willing to use effective contraceptives from screening to the 6 months after the last dose administration;
- •Subjects judged to be in good health by the investigator, based on the physical examination, vital signs examination, 12-lead electrocardiogram (ECG) examination and laboratory examination etc;
Exclusion Criteria
- •History of allergic conditions, or allergic to any ingredients of DBPR108;
- •History of severe diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematological, psychiatric/neurological systems diseases within 1 year prior to screening;
- •History of hypoglycemia or abnormal blood glucose at screening: fasting blood glucose \<70 mg/dL (3.9 mmol/L) or \>110 mg/dL (6.1 mmol/L);
- •Subjects who have previously undergone surgery (e.g., subtotal gastrectomy) that may affect the absorption, distribution, metabolism, or excretion of the drug, or who have a scheduled surgery during the study period;
- •History of drug abuse, or urine drug screening is positive at screening;
- •Smoking more than 5 cigarettes per day within 3 months prior to screening, or who cannot stop using nicotine-containing products during the study period;
- •Regular alcohol consumption exceeding 15 g/day(female) or 25 g/day(male) (15 g ≈ 450 mL beer, or 50 mL hard liquor, or 150 mL wine) within the 3 months prior to screening, or taking any product containing alcohol within 48 h before dosing, or alcohol test is positive;
- •Blood donation (or blood loss) ≥400 mL, or receiving blood product transfusion within 3 months prior to screening;
- •Consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks), or those who have had strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, within 48 h before the administration;
- •Use of any prescription drug, over-the-counter drug (except acetaminophen and some nasal sprays), or herbal medicine within 2 weeks prior to screening;
Arms & Interventions
Sequence A administered DBPR108
Subjects will receive a single dose of DBPR108 100 mg under fasted condition, following a low-fat meal and a standard meal.
Intervention: DBPR108 tablets
Sequence B administered DBPR108
Subjects will receive a single dose of DBPR108 100 mg following a low-fat meal and standard meal, under fasted condition.
Intervention: DBPR108 tablets
Sequence C administered DBPR108
Subjects will receive a single dose of DBPR108 100 mg following a standard meal, under fasted condition, following a low-fat meal.
Intervention: DBPR108 tablets
Outcomes
Primary Outcomes
Peak plasma concentration (Cmax) of DBPR108
Time Frame: Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Area under the plasma concentration versus time curve from time zero to the time of last measurable concentration (AUClast) of DBPR108
Time Frame: Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Area under the plasma concentration versus time curve from time zero to infinity (AUCinf) of DBPR108
Time Frame: Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary Outcomes
- Apparent clearance (CL/F) of DBPR108(Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.)
- Apparent volume of Distribution (Vz/F) of DBPR108(Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.)
- Time to achieve maximum plasma concentration (Tmax) of DBPR108(Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.)
- Half-life (t1/2) of DBPR108(Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.)
- Number of subjects with treatment-related adverse events as assessed by CTCAE v5.0(Day 1 to Day 14)